| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1899b1e1994962b650fdcebd167a7a2f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 |
| filingDate |
2013-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dac6a21deda737a2713c5bcbe1600760
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cb7df63e64a34d03d74d88e411e8417
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dbcf1de0da0b5c40cbd71411abd88e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cab4382b6e7fb6b292c94149bf1365c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cfd125888ceb1a4d75921a809bdee5c |
| publicationDate |
2016-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CY-1114263-T1 |
| titleOfInvention |
DOSAGE FORM OF PRAMPEXOLIS SPONSORED ON A DAY |
| abstract |
An oral pharmaceutical composition comprising a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition displaying at least one of the following: (a) release profile in the test tube which on average no more than 20% of pramipexole dissolves within two hours of placement of the composition in a standard dissolution test; and (b) absorption profile of pramipexole in vitro after administration The single dose to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and / or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once a day, to a person who has a condition or disorder that is indicated by a dopamine receptor agonist. |
| priorityDate |
2002-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |